{
    "ticker": "BHVN",
    "name": "Biohaven Pharmaceutical Holding Company Ltd.",
    "description": "Biohaven Pharmaceutical Holding Company Ltd. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for neurological diseases and disorders. Founded in 2013 and headquartered in New Haven, Connecticut, Biohaven focuses on addressing the unmet needs of patients suffering from debilitating conditions like migraine and other neurological disorders. The company's flagship product, Nurtec ODT (rimegepant), is a novel oral dissolving tablet that provides acute treatment for migraine and has been recognized for its efficacy and rapid onset of action. Biohaven is also advancing its pipeline of next-generation therapies, including treatments for conditions such as Alzheimer's disease and other neurodegenerative diseases. The company's mission is to transform the treatment landscape of neurological disorders and improve patients' quality of life through cutting-edge research and development. Biohaven aims to leverage its expertise in neuroscience and drug development to bring forth innovative solutions that address the complexities of brain health.",
    "industry": [
        "Biopharmaceuticals",
        "Healthcare"
    ],
    "headquarters": "New Haven, Connecticut, USA",
    "founded": "2013",
    "website": "https://www.biohavenpharma.com",
    "ceo": "Vlad Coric",
    "social_media": {
        "twitter": "https://twitter.com/BiohavenPharma",
        "linkedin": "https://www.linkedin.com/company/biohaven-pharmaceuticals"
    },
    "investor_relations": "https://investors.biohavenpharma.com",
    "key_executives": [
        {
            "name": "Vlad Coric",
            "position": "CEO"
        },
        {
            "name": "Gregory W. M. McGowan",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Migraine Treatments",
            "products": [
                "Nurtec ODT"
            ]
        },
        {
            "category": "Neurological Disorder Treatments",
            "products": [
                "Other pipeline candidates"
            ]
        }
    ],
    "seo": {
        "meta_title": "Biohaven Pharmaceutical | Innovative Neurological Treatments",
        "meta_description": "Explore Biohaven Pharmaceutical, a leader in developing innovative therapies for neurological diseases. Learn about our mission and groundbreaking products.",
        "keywords": [
            "Biohaven",
            "Neurology",
            "Migraine Treatment",
            "Pharmaceuticals",
            "Innovative Therapies"
        ]
    },
    "faq": [
        {
            "question": "What is Biohaven known for?",
            "answer": "Biohaven is known for its innovative therapies for neurological diseases, including its flagship product Nurtec ODT for migraine treatment."
        },
        {
            "question": "Who is the CEO of Biohaven?",
            "answer": "Vlad Coric is the CEO of Biohaven Pharmaceutical."
        },
        {
            "question": "Where is Biohaven headquartered?",
            "answer": "Biohaven is headquartered in New Haven, Connecticut, USA."
        },
        {
            "question": "What is Nurtec ODT?",
            "answer": "Nurtec ODT is a novel oral dissolving tablet used for the acute treatment of migraine."
        },
        {
            "question": "When was Biohaven founded?",
            "answer": "Biohaven was founded in 2013."
        }
    ],
    "competitors": [
        "MRNA",
        "VRTX",
        "AVEO",
        "ALNY"
    ],
    "related_stocks": [
        "PFE",
        "JNJ",
        "ABBV",
        "AMGN"
    ]
}